IMMP Immutep

Immutep Receives A$4.6 million R&D Tax Incentive from French Government

Immutep Receives A$4.6 million R&D Tax Incentive from French Government

Media Release

SYDNEY, AUSTRALIA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, is pleased to announce it has received a €2,588,954 (~ A$4,567,769 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).

The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.

Immutep qualifies for the CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France. The cash payment is provided in respect of expenditure incurred on eligible R&D activities conducted in the European Union in the 2024 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government’s R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.

The funds will be used to support the ongoing and planned global clinical development of eftilagimod alfa and IMP761.

About Immutep

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit .

Australian Investors/Media:

Eleanor Pearson, Sodali & Co

+61 (0)400 886 722;

U.S. Investors/Media:

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000;



EN
03/11/2025

Underlying

IMMPImmutep

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immutep

 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commer...

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyd...

December 8, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San An...

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in heavily pretreated metastatic breast cancer patientsAIPAC-003 has resulted in successful completion of FDA’s Project Optimus requirements and selection of 30 mg as efti’s optimal biological dose SYDNEY, AUSTRALIA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting ...

December 2, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Translational Data and Significant Pathologic Response Rates from EFTI...

Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025 Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue sarcoma subtypes including rare and highly aggressive tumours with poor prognosisEarly translational data show a strong immune system activation inline with efti’s mode of action with statistically-significant increases in multiple cytokines and chemokines High levels of key immune proteins in EFTISARC-NEO including ...

November 13, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Receives A$4.6 million R&D Tax Incentive from French Governmen...

Immutep Receives A$4.6 million R&D Tax Incentive from French Government Media Release SYDNEY, AUSTRALIA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, is pleased to announce it has received a €2,588,954 (~ A$4,567,769 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which ...

November 3, 2025 1 EN
 PRESS RELEASE
Free
IMMP IMMUTEP

Immutep Quarterly Activities Report Q1 FY26

Immutep Quarterly Activities Report Q1 FY26 Media Release Pivotal TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in first line non-small cell lung cancer continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countriesTrial in Progress poster for TACTI-004 presented at the World Conference on Lung Cancer (WCLC) 2025, where physician feedback continued to be encouragingPositive feedback received from the FDA regarding future late-stage clinical development of efti in first line head and neck cancer patients with...

October 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch